Disclosures: Richard Dean: Nothing to Disclose, Maryam Yazdanfar: Nothing to Disclose, Joseph Benjamin Zepeda: Nothing to Disclose, Isha Patel: Nothing to Disclose, Cynthia Levy: Cymabay: Grant/Research Support, Cymabay: Consultant, Intercept: Grant/Research Support, Intercept: Consultant, Calliditas: Grant/Research Support, Calliditas: Consultant, GSK: Consultant, GSK: Grant/Research Support, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, Mirum: Consultant, Zydus: Grant/Research Support, Gilead: Grant/Research Support, Gilead: Consultant, Escient: Grant/Research Support, Kowa: Grant/Research Support, Kowa: Consultant, Genfit: Grant/Research Support, COur: Advisor, Chemomab: Consultant, Craig Lammert: Nothing to Disclose, Raghav Bordia: Nothing to Disclose, Duru Cosar: Nothing to Disclose, Katherine Specht: Nothing to Disclose, Daniel Pratt: Nothing to Disclose, Stuart Gordon: Nothing to Disclose, Lisa Forman: Nothing to Disclose, Fawzy Barry: Nothing to Disclose, Michael Li: Nothing to Disclose, David Assis: Nothing to Disclose, Ashleigh McGirr: Nothing to Disclose, Megan McLaughlin: Nothing to Disclose, Sumanta Mukherjee: GSK: Own GSK stocks, Usha Gungabissoon: GSK: Employee and stockholder, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support 2384 FOSB AGGRAVATES CHOLESTATIC LIVER DISEASE BY DISRUPTING IMMUNE MICROENVIRONMENT BALANCE jintao Xiao 1 haiyue He 2 ziyi Zhao 2 yuhao Zhu 2 wenhu Li 2 xingyang Luo 2 linxiang Zhou 2 xiaomei Zhao 2 xiaowei Liu 2 , 1 Xiangya Hospital Central South University, 2 XiangyaHospital Central South University Background: Bile acid accumulation is a prominent feature of cholestatic liver disease(CLD), and plays a crucial role as a trigger for hepatic immune dysregulation and hepatocyte damage
Who should not take daily glutathione
Eleven (30.5%) patients were receiving nivolumab plus ipilimumab (like our patient)
Ce qui engendre des douleurs abdominales, un accroissement du risque de cancer, une insuffisance hpatique et des affections rnales
